Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17) Academic Article uri icon


MeSH Major

  • Chromosome Aberrations
  • Chromosomes, Human, Pair 15
  • Chromosomes, Human, Pair 17
  • Drug Resistance, Neoplasm
  • Leukemia, Promyelocytic, Acute


  • This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or all-trans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

publication date

  • September 2012



  • Academic Article



  • eng

PubMed Central ID

  • PMC3568758

Digital Object Identifier (DOI)

  • 10.1007/s12032-012-0251-7

PubMed ID

  • 22729365

Additional Document Info

start page

  • 2095

end page

  • 101


  • 29


  • 3